

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

26 Jun 2026

### A comparative study of the effect of Bractant and Corosurf on the duration of oxygen requirement in premature babies with respiratory distress syndrome with a gestational age of less than 32 weeks

#### Protocol summary

##### Study aim

A comparative study of the effect of Bractant and Corosurf on the duration of oxygen requirement in premature babies with respiratory distress syndrome

##### Design

This is a randomized, single-blinded clinical trial with a parallel design. This randomized study will be conducted on 58 premature babies with respiratory distress. A random block is used for randomization and the participants are assigned to two intervention groups.

##### Settings and conduct

This study, which will be conducted at Imam Reza Hospital in Kermanshah, is a single-blinded study. Surfactant injection at a dose of 100 mg/kg will be done through intrapulmonary intubation under sterile conditions and as instillation into the tube, and after instilling the surfactant, the baby will be ventilated and the tracheal tube will be removed and the baby will be treated with NCPAP or HFNC (INSURE).

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Premature babies less than 32 weeks with respiratory distress syndrome; Infants who need surfactant  
Exclusion criteria: Existence of other respiratory diseases other than respiratory distress syndrome; Congenital heart abnormalities; A history of resuscitation at birth with severe metabolic vasculitis

##### Intervention groups

In the first intervention group, in the first 12 hours after birth, they will receive the manufactured Berketant surfactant (manufactured by Tekzima, Iran), an 8cc vial prepared from pig lungs. The second intervention group will receive Corosurf surfactant (manufactured by Cheisi, Italy) in a 3 cc vial prepared from pig lungs in the first 12 hours after birth.

##### Main outcome variables

Duration of NICU stay

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20130812014333N210**

Registration date: **2023-09-13, 1402/06/22**

Registration timing: **prospective**

Last update: **2023-09-13, 1402/06/22**

Update count: **0**

##### Registration date

2023-09-13, 1402/06/22

##### Registrant information

##### Name

Feizollah Foroughi

##### Name of organization / entity

Kermanshah University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 83 1821 4653

##### Email address

fforoughi@kums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-09-21, 1402/06/30

##### Expected recruitment end date

2024-05-19, 1403/02/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

### Scientific title

A comparative study of the effect of Bractant and Corosurf on the duration of oxygen requirement in premature babies with respiratory distress syndrome with a gestational age of less than 32 weeks

### Public title

A comparative study of the effect of Bractant and Corosurf on the duration of oxygen requirement in premature babies with respiratory distress syndrome

### Purpose

Treatment

### Inclusion/Exclusion criteria

#### Inclusion criteria:

Premature babies less than 32 weeks with respiratory distress syndrome Infants who need surfactant

#### Exclusion criteria:

Existence of other respiratory diseases other than respiratory distress syndrome Congenital heart abnormalities A history of resuscitation at birth with severe metabolic vasculitis

### Age

From **1 day** old to **30 days** old

### Gender

Both

### Phase

N/A

### Groups that have been masked

- Care provider

### Sample size

Target sample size: **58**

### Randomization (investigator's opinion)

Randomized

### Randomization description

Randomization using the blocking method with blocks in sizes 6 and 9. For randomization, the site <https://www.sealedenvelope.com> is used. All codes are recorded on paper and stored in specific envelopes. Each of the generated codes is kept separately inside the envelope and the secretary gives one of these envelopes to the patient before the patient enters the doctor's room. Accordingly, the next patient code is not predictable. The doctor determines which treatments to perform based on the patient's code. Only the physician performing the intervention will be aware of the code assigned to the patient. After evaluating the outcome, based on the patient's name, the collected information will be linked to the assigned code.

### Blinding (investigator's opinion)

Single blinded

### Blinding description

Medications can only be identified by the serial number on the container. The serials are with the main researcher and will remain confidential until the end of the study. The charge of injecting medications will not know about the assignment of individuals to groups.

### Placebo

Not used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Kermanshah University of Medical Sciences

##### Street address

Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences, Building No.2, Shahid Beheshti Boulevard

##### City

Kermanshah

##### Province

Kermanshah

##### Postal code

6715847141

#### Approval date

2023-05-13, 1402/02/23

#### Ethics committee reference number

IR.KUMS.MED.REC.1402.061

## Health conditions studied

### 1

#### Description of health condition studied

Distress syndrome of neonates

#### ICD-10 code

P22.0

#### ICD-10 code description

Respiratory distress syndrome of newborn

## Primary outcomes

### 1

#### Description

Duration of NICU stay

#### Timepoint

End of study

#### Method of measurement

Based on the hospitalization record

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

In the first intervention group, in the first 12 hours after

birth, they will receive the manufactured Berketant surfactant (manufactured by Tekzima, Iran), an 8cc vial prepared from pig lungs

**Category**

Treatment - Drugs

**2****Description**

The second intervention group will receive Corosurf surfactant (manufactured by Cheisi, Italy) in a 3 cc vial prepared from pig lungs in the first 12 hours after birth.

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Emam Reza Hospital

**Full name of responsible person**

Maryam Reza Beigi

**Street address**

Emam Reza Hospital, Parastar Boulevard

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6715847141

**Phone**

+98 83 3427 6306

**Email**

maryamrezabeigi1358@gmail.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

Dr. Cyrus Jalili

**Street address**

Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences, Building No.2, Shahid Beheshti Boulevard

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6715847141

**Phone**

+98 83 3836 0014

**Email**

cjalili@kums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Kermanshah University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

Maryam Reza Beigi

**Position**

Resident of Pediatric

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Pediatrics

**Street address**

Emam Reza Hospital, Parastar Boulevard

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6715847141

**Phone**

+98 83 3427 6306

**Email**

maryamrezabeigi1358@gmail.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

Dr. Noushin Miladi

**Position**

Member of the academic staff of Kermanshah University of Medical Sciences

**Latest degree**

Specialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Emam Reza Hospital, Parastar Boulevard

**City**

Kermanshah

**Province**

Kermanshah

**Postal code**

6715847141

**Phone**

+98 83 3427 6306

**Email**

maryamrezabeigi1358@gmail.com

Kermanshah

**Postal code**

6715847141

**Phone**

+98 83 3427 6306

**Email**

maryamrezabeigi1358@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Kermanshah University of Medical Sciences

**Full name of responsible person**

Maryam Reza Beigi

**Position**

Resident of Pediatric

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Pediatrics

**Street address**

Emam Reza Hospital, Parastar Boulevard

**City**

kermanshah

**Province****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no further information

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available